We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Theravance Stock Down 3% After Zymeworks Announces Buyout
Read MoreHide Full Article
Key Takeaways
Theravance agreed to a $929 million all-cash acquisition expected to close in the second half of 2026.
TBPH pursued a sale after its ampreloxetine study failed, ending the program and prompting restructuring.
TBPH holders get $17.00 per share in cash plus rights to 80% of future ampreloxetine monetization proceeds.
Shares of Theravance Biopharma (TBPH - Free Report) sank by around 3% on June 29, 2026, after the company announced a definitive agreement with Zymeworks Inc. (ZYME - Free Report) under which the latter will acquire TBPH in an all-cash transaction valued at approximately $929 million. The acquisition is expected to close in the second half of this year.
The deal followed a strategic review initiated after Theravance's growth outlook deteriorated significantly. The company relied primarily on collaboration revenues from its 35% share of U.S. profits from Viatris' (VTRS - Free Report) marketed COPD therapy, Yupelri (revefenacin), leaving it dependent on a single commercial asset.
The company’s long-term growth strategy was centered on its lead candidate, ampreloxetine, a norepinephrine reuptake inhibitor being developed for symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy.
However, in early March, the pivotal phase III CYPRESS study failed to meet its primary and secondary endpoints despite demonstrating biological activity.
Consequently, TBPH decided to wind down the ampreloxetine program. Following the setback, the company launched a broad strategic review, explored value-maximizing alternatives, including a potential sale and implemented a major organizational restructuring to reduce costs.
Per management, the Zymeworks acquisition is the most value-maximizing option for Theravance shareholders after evaluating all available strategic alternatives.
Over the past three months, TBPH shares have risen 5.1% against the industry’s 3.7% decline.
Image Source: Zacks Investment Research
Key Highlights of the Acquisition Deal
Per the deal, Theravance shareholders will receive $17.00 in cash for each outstanding share, representing a 22% premium to the company's closing price on March 3, 2026, the day TBPH announced topline data from the phase III CYPRESS study of ampreloxetine and a 10% premium to its volume-weighted average share price since then. Shareholders of Theravance will receive a contingent value right entitling them to 80% of any net proceeds generated from the future licensing, divestiture or other monetization of ampreloxetine over the next 10 years, with the remaining 20% accruing to Zymeworks.
However, if no monetization transaction for ampreloxetine is completed before the acquisition closes, a Theravance-appointed representative will continue to pursue licensing, divestiture or other monetization opportunities on behalf of ZYME for up to 12 months following closing.
TBPH's Zacks Rank
Theravance currently carries a Zacks Rank #4 (Sell).
View the Zacks #1 Rank List
Image: Bigstock
Theravance Stock Down 3% After Zymeworks Announces Buyout
Key Takeaways
Shares of Theravance Biopharma (TBPH - Free Report) sank by around 3% on June 29, 2026, after the company announced a definitive agreement with Zymeworks Inc. (ZYME - Free Report) under which the latter will acquire TBPH in an all-cash transaction valued at approximately $929 million. The acquisition is expected to close in the second half of this year.
The deal followed a strategic review initiated after Theravance's growth outlook deteriorated significantly. The company relied primarily on collaboration revenues from its 35% share of U.S. profits from Viatris' (VTRS - Free Report) marketed COPD therapy, Yupelri (revefenacin), leaving it dependent on a single commercial asset.
The company’s long-term growth strategy was centered on its lead candidate, ampreloxetine, a norepinephrine reuptake inhibitor being developed for symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy.
However, in early March, the pivotal phase III CYPRESS study failed to meet its primary and secondary endpoints despite demonstrating biological activity.
Consequently, TBPH decided to wind down the ampreloxetine program. Following the setback, the company launched a broad strategic review, explored value-maximizing alternatives, including a potential sale and implemented a major organizational restructuring to reduce costs.
Per management, the Zymeworks acquisition is the most value-maximizing option for Theravance shareholders after evaluating all available strategic alternatives.
Over the past three months, TBPH shares have risen 5.1% against the industry’s 3.7% decline.
Image Source: Zacks Investment Research
Key Highlights of the Acquisition Deal
Per the deal, Theravance shareholders will receive $17.00 in cash for each outstanding share, representing a 22% premium to the company's closing price on March 3, 2026, the day TBPH announced topline data from the phase III CYPRESS study of ampreloxetine and a 10% premium to its volume-weighted average share price since then. Shareholders of Theravance will receive a contingent value right entitling them to 80% of any net proceeds generated from the future licensing, divestiture or other monetization of ampreloxetine over the next 10 years, with the remaining 20% accruing to Zymeworks.
However, if no monetization transaction for ampreloxetine is completed before the acquisition closes, a Theravance-appointed representative will continue to pursue licensing, divestiture or other monetization opportunities on behalf of ZYME for up to 12 months following closing.
TBPH's Zacks Rank
Theravance currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.